| Literature DB >> 34350485 |
Zhiming Lv1, Dongwei Xiong1, Jichao Shi2, Miao Long3, Zeliang Chen4.
Abstract
As the main pathogen threatening human and animal health, viruses can affect the immunity and metabolism of bodies. There are innate microbial barriers in the digestive tract of the body to preserve the homeostasis of the animal body, which directly or indirectly influences the host defence against viral infection. Understanding the interaction between viruses and intestinal microbiota or probiotics is helpful to study the pathogenesis of diseases. Here, we review recent studies on the interaction mechanism between intestinal microbiota and viruses. The interaction can be divided into two aspects: inhibition of viral infection by microbiota and promotion of viral infection by microbiota. The treatment of viral infection by probiotics is summarized.Entities:
Mesh:
Year: 2021 PMID: 34350485 PMCID: PMC8336530 DOI: 10.1007/s00284-021-02623-5
Source DB: PubMed Journal: Curr Microbiol ISSN: 0343-8651 Impact factor: 2.188
Fig. 1Physiological function of intestinal microbiota. The maintenance of normal physiological function of intestinal microbiota needs coordination in many aspects. The variety and heredity of animals, dietary factors, the use of antibiotics, stress, and changes in surrounding environment may affect the intestinal microbiota of the body
Fig. 2The interaction between virus and intestinal microbiota. The promoting mechanisms include: 1. enhance the infectivity of virus (stabilize the structure of virus and increase the differentiation of target cells); 2. destroy the immune system of the body and weaken the defence against virus. The antagonistic mechanisms include: 1. bacteria and their metabolites directly fight viruses; 2. bacteria and their metabolites eliminate viruses by mobilizing the body’s immune system
The relationship between virus infection and gut microbiome
| Virus | Intestinal microbiota changes caused by infection | Interaction mechanism |
|---|---|---|
| PV | Not reported | ➀ LPS or peptidoglycan can enhance virus activity [ |
| ➁ LPS can enhance the binding ability of viruses and cell surface receptors [ | ||
| ➂ LPS or other polysaccharide components can enhance virus stability [ | ||
| NV | Lactobacillaceae populations were significantly decreased [ | ➀ Type 2 cytokines can induce tuft cell proliferation and promote MNoV infection in vivo [ |
| α-diversity was increased [ | ➁ HBGA can bind to viral capsid protein and enhance its ability to infect cells [ | |
| ➂ Bile acid can change the structure of intestinal flora and regulate viral regionalization [ | ||
| RV | Lactobacillus species reduced from the ileum; Bacteroides and Akkermansia were increased [ | Segmented filamentous bacteria (SFB) can directly reduce the rotavirus infectivity and accelerate the renewal of infected epithelial cells to help mice resist viral infections [ |
| TEGV | Lactobacillus was reduced. Enterobacteriaceae was enriched | Epithelial–mesenchymal transition enhances the adhesion of the secondary pathogen ETEC K88 [ |
| HIV | Lactobacillus were significantly lower. | ➀ Primarily mediated indirectly through increased expression of CCR5 on LP CD4 T cells without concomitant large scale T cell activation [ |
| α-Diversity was decreased [ | ➁ Loss of immune cells and gut microbiota dysbiosis contribute to structural damage to the GI tract and systemic translocation of GI tract microbial products [ | |
| RSV | S24_7, Clostridiales, Odoribacteraceae, Lactobacillaceae, and Actinomyces were increased. Severe α-diversity was decreased [ | ➀ Intestinal microbiota significantly stimulated IL-17 production from intestinal epithelial cells, which subsequently promoted Th17 cell polarization reduced intestinal injury [ |
| ➁ Acetic acid can activate IFN-β by regulating GPR43 and interferon receptor to exert antiviral activity [ |
Fig. 3LPS enhances virus infectivity. LPS, as a component of bacteria, can enhance the thermal stability of the virus, enhance the adhesion between the virus and the receptor cells, and enhance the infectivity of the virus. It is an important part in the process of viral invasion of the body
Clinical efficacy of probiotics on infectious diseases
| Strain | Target Disease (Virus) | Individuality | Result | Refs |
|---|---|---|---|---|
| HCV | Anti-HCV-positive adults | AST and ALT were detected | [ | |
| HIV | HIV-infected child | Enhance immune response | [ | |
| Cytomegalovirus Epstein–Barr | Healthy athletes | Reduced plasma CMV and EBV antibody titres | [ | |
| HIV | HIV-infected child | CD4 + T cells increase; induced decreases in plasma HIV load and CD8 + T- ell activation | [ | |
| Norovirus | Elderly people | No significant difference in infection rate | [ | |
| Rhinovirus | Preterm infant | Reduce the risk of rhinovirus infections | [ | |
| Rotavirus and | 6 M-5Y children with rotavirus and cryptosporidial gastroenteritis | Decrease repeated episodes of rotavirus diarrhoea; improvement in intestinal function in children with rotavirus and cryptosporidial gastroenteritis | [ | |
| Cats latent feline herpesvirus 1 | FHV1-infected cats | Reduce incidence rate | [ | |
| Non-rotavirus | Infant with diarrhoea | Ineffective in those with rotavirus diarrhoea | [ | |
| Common cold | Elderly adults | Reduced the incidence rate of the common cold | [ | |
| Minimal hepatic encephalopathy (MHE) in patients with hepatitis B virus (HBV)-induced liver cirrhosis | HBV-induced liver cirrhosis patients | Reduction in venous ammonia; the parameters of the intestinal mucosal barrier were obviously improved | [ | |
| Rotavirus and poliovirus | Six-week-old healthy, full-term infants | Anti-rotavirus- and anti-poliovirus-specific IgA increased | [ | |
| Bifidobacterium | Acute viral diarrhoea (rotavirus) | Children(3 months and 3 years) | Reduce diarrhoea and promote viral shedding | [ |
| Acute rotavirus diarrhoea | Children (3 months–5 years) | The duration of diarrhoea was significantly shorter | [ |
HCV hepatitis C virus, AST aspartate aminotransferase, ALT alanine aminotransferase, HIV human immunodeficiency virus, CMV cytomegalovirus, EBV epstein–barr virus, FHV1 feline herpesvirus 1, MHE minimal hepatic encephalopathy, HBV hepatitis B virus